Lazard Asset Management’s Intellia Therapeutics NTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $866K | Sell |
92,430
-15,627
| -14% | -$146K | ﹤0.01% | 1345 |
|
|
2025
Q1 | $768K | Sell |
108,057
-1,443
| -1% | -$10.3K | ﹤0.01% | 1298 |
|
|
2024
Q4 | $1.28M | Buy |
109,500
+7,488
| +7% | +$87.3K | ﹤0.01% | 1048 |
|
|
2024
Q3 | $2.1M | Sell |
102,012
-14,378
| -12% | -$295K | ﹤0.01% | 862 |
|
|
2024
Q2 | $2.6M | Buy |
116,390
+26,332
| +29% | +$589K | ﹤0.01% | 813 |
|
|
2024
Q1 | $2.48M | Sell |
90,058
-12,175
| -12% | -$335K | ﹤0.01% | 803 |
|
|
2023
Q4 | $3.12M | Sell |
102,233
-3,917
| -4% | -$119K | ﹤0.01% | 778 |
|
|
2023
Q3 | $3.35M | Sell |
106,150
-1,329
| -1% | -$42K | ﹤0.01% | 780 |
|
|
2023
Q2 | $4.38M | Buy |
107,479
+1,021
| +1% | +$41.6K | 0.01% | 730 |
|
|
2023
Q1 | $3.97M | Buy |
106,458
+58,951
| +124% | +$2.2M | 0.01% | 774 |
|
|
2022
Q4 | $1.66M | Sell |
47,507
-39,889
| -46% | -$1.39M | ﹤0.01% | 927 |
|
|
2022
Q3 | $4.89M | Buy |
87,396
+4,971
| +6% | +$278K | 0.01% | 719 |
|
|
2022
Q2 | $4.27M | Buy |
82,425
+81,876
| +14,914% | +$4.24M | 0.01% | 765 |
|
|
2022
Q1 | $39K | Buy |
549
+146
| +36% | +$10.4K | ﹤0.01% | 1860 |
|
|
2021
Q4 | $47K | Buy |
403
+393
| +3,930% | +$45.8K | ﹤0.01% | 1767 |
|
|
2021
Q3 | $1K | Buy |
+10
| New | +$1K | ﹤0.01% | 2131 |
|